In patients surviving #stroke, approximately 15% and 60% exhibit concurrent #diabetes mellitus and #overweight/obesity, respectively, necessitating heightened secondary prevention efforts. Despite glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrating improved outcomes for those with diabetes mellitus or obesity, their underutilization persists among eligible individuals

http://2medical.news/2024/06/27/glucagon-like-peptide-1-receptor-agonists-and-stroke-a-systematic-review-and-meta-analysis-of-cardiovascular-outcome-trials